IRS1 and neoplasm: In breast cancers, IRS-1 and IRS-2 are the two major isoforms mediating IGF/insulin signalling; IRS-1 promotes tumour growth, whereas IRS-2 stimulates motility.19–22 Despite initial optimism, clinical trials targeting IGF1Rβ have been disappointing.